123 related articles for article (PubMed ID: 29374758)
1. Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines.
Friedrich M; Reichert K; Woeste A; Polack S; Fischer D; Hoellen F; Rody A; Köster F; Thill M
Anticancer Res; 2018 Feb; 38(2):1201-1207. PubMed ID: 29374758
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitors.
Thill M; Reichert K; Woeste A; Polack S; Fischer D; Hoellen F; Rody A; Friedrich M; Köster F
Anticancer Res; 2015 Feb; 35(2):1189-95. PubMed ID: 25667510
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway.
Wang G; Li J; Zhang L; Huang S; Zhao X; Zhao X
Biochem Biophys Res Commun; 2017 Aug; 490(3):969-976. PubMed ID: 28666869
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Sugimoto T; Bartholomeusz C; Tari AM; Ueno NT
Breast Cancer Res; 2007; 9(4):R41. PubMed ID: 17612393
[TBL] [Abstract][Full Text] [Related]
5. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
[TBL] [Abstract][Full Text] [Related]
7. Influence of calcitriol on prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cell lines.
Thill M; Cordes T; Hoellen F; Becker S; Dittmer C; Kümmel S; Salehin D; Friedrich M; Diedrich K; Köster F
Anticancer Res; 2012 Jan; 32(1):359-65. PubMed ID: 22213327
[TBL] [Abstract][Full Text] [Related]
8. Curcumin-Celecoxib: a synergistic and rationale combination chemotherapy for breast cancer.
Alqahtani AM; Chidambaram K; Pino-Figueroa A; Chandrasekaran B; Dhanaraj P; Venkatesan K
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1916-1927. PubMed ID: 33660801
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D inhibits ovarian cancer cell line proliferation in combination with celecoxib and suppresses cyclooxygenase-2 expression.
Thill M; Woeste A; Reichert K; Fischer D; Rody A; Friedrich M; Köster F
Anticancer Res; 2015 Feb; 35(2):1197-203. PubMed ID: 25667511
[TBL] [Abstract][Full Text] [Related]
10. The effects of celecoxib on the proliferation and ultrastructural changes of MDA-MB-231 breast cancer cells.
Ma Q; Gao Y; Wei DF; Jiang NH; Ding L; He X; Wei L; Zhang JW
Ultrastruct Pathol; 2018; 42(3):289-294. PubMed ID: 29668331
[TBL] [Abstract][Full Text] [Related]
11. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells.
Jeon YW; Suh YJ
Oncol Rep; 2013 Feb; 29(2):819-25. PubMed ID: 23229294
[TBL] [Abstract][Full Text] [Related]
12. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
13. Molecular and Metabolomic Investigation of Celecoxib Antiproliferative Activity in Mono-and Combination Therapy against Breast Cancer Cell Models.
Bardaweel SK; Dahabiyeh LA; Akileh BM; Shalabi DD; AlHiary AK; Pawling J; Dennis JW; Rahman AMA
Anticancer Agents Med Chem; 2022; 22(8):1611-1621. PubMed ID: 34515014
[TBL] [Abstract][Full Text] [Related]
14. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
Suh YJ; Chada S; McKenzie T; Liu Y; Swisher SG; Lucci A; Hunt KK
Surgery; 2005 Sep; 138(3):422-30. PubMed ID: 16213894
[TBL] [Abstract][Full Text] [Related]
15.
DE Cremoux P; Hamy AS; Lehmann-Che J; Scott V; Sigal B; Mathieu MC; Bertheau P; Guinebretière JM; Pierga JY; Giacchetti S; Brain E; Marty M; Asselain B; Spyratos F; Bièche I
Anticancer Res; 2018 Mar; 38(3):1485-1490. PubMed ID: 29491076
[TBL] [Abstract][Full Text] [Related]
16. Additive effects of ulinastatin and docetaxel on growth of breast cancer xenograft in nude mice and expression of PGE2, IL-10, and IL-2 in primary breast cancer cells.
Zhong B; Shen H; Sun X; Wang H; Zhang Y; Sun Z
Cancer Biother Radiopharm; 2012 May; 27(4):252-8. PubMed ID: 22594905
[TBL] [Abstract][Full Text] [Related]
17. Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53.
Katkoori VR; Manne K; Vital-Reyes VS; Rodríguez-Burford C; Shanmugam C; Sthanam M; Manne U; Chatla C; Abdulkadir SA; Grizzle WE
Biotech Histochem; 2013 Jan; 88(1):38-46. PubMed ID: 23167625
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 expression is induced by celecoxib treatment in lung cancer cells and is transferred to neighbor cells via exosomes.
Kim J; Hong SW; Kim S; Kim D; Hur DY; Jin DH; Kim B; Kim YS
Int J Oncol; 2018 Feb; 52(2):613-620. PubMed ID: 29345286
[TBL] [Abstract][Full Text] [Related]
19. The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231 through inhibition of BCL-2: potential for breast cancer therapeutics.
Brosseau C; Colston K; Dalgleish AG; Galustian C
Apoptosis; 2012 Feb; 17(2):164-73. PubMed ID: 22109882
[TBL] [Abstract][Full Text] [Related]
20. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines.
Elstner E; Linker-Israeli M; Said J; Umiel T; de Vos S; Shintaku IP; Heber D; Binderup L; Uskokovic M; Koeffler HP
Cancer Res; 1995 Jul; 55(13):2822-30. PubMed ID: 7796409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
